Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine
作者： Charles Zacharchuk , Susan Quinn , Florence Binlich , Kenneth Wang
DOI:
关键词:
摘要: A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and capecitabine in the treatment neoplasm is provided. Regimens, kits, methods for neoplasm, including breast cancer metastatic cancer, lung using this combination, optionally with other anti-neoplastic agents, or immune modulators are also described.
lens.org参考文章(480)
John Farley, Michael J. Birrer, Novel Therapeutic Targets Cancer Treatment and Research. ,vol. 149, pp. 63- 84 ,(2009) , 10.1007/978-0-387-98094-2_3
A Zaczek, K P Bielawski, B Brandt, The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histology and Histopathology. ,vol. 20, pp. 1005- 1015 ,(2005) , 10.14670/HH-20.1005
John S. Coon, Susan S. Jewell, Larry E. Morrison, Diagnostics method for identifying candidate patients for the treatment with trastuzumab ,(2006)
David W. Fry, Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacology & Therapeutics. ,vol. 82, pp. 207- 218 ,(1999) , 10.1016/S0163-7258(98)00050-3
Monica Fornier, Conleth G. Murphy, HER2-positive breast cancer: beyond trastuzumab. Oncology. ,vol. 24, pp. 410- 415 ,(2010)
Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer, Beyond Trastuzumab: Second-Generation Targeted Therapies for HER-2-positive Breast Cancer Springer, Basel. pp. 91- 107 ,(2011) , 10.1007/978-3-0346-0094-1_6
Alan Berezov, Natalie Minkovsky, BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Current opinion in investigational drugs. ,vol. 9, pp. 1336- ,(2008)
Eric Ehrnsperger, Christopher Richard Diorio, Syed M. Shah, Solid dosage formulations ,(2007)
Mark D. Pegram, Gottfried Konecny, Dennis J. Slamon, The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer treatment and research. ,vol. 103, pp. 57- 75 ,(2000) , 10.1007/978-1-4757-3147-7_4
Kyoko Hida, Dhara N. Amin, Michael Klagsbrun, Method to prognose response to anti-egfr therapeutics ,(2006)